How to Diagnose and Treat Medically Women with Excessive Hair

Dermatologic Clinics

Volumn 31, Issue 1, 2013, Pages 57-65

  Blume Peytavi, Ulrike ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Excessive hair; Hirsutism; Hypertrichosis; Laser epilation; Pharmacologic treatment

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CHLORMADINONE ACETATE; CYPROTERONE ACETATE; DIENOGEST; DROSPIRENONE; EFLORNITHINE; ETHINYLESTRADIOL; FINASTERIDE; FLUTAMIDE; KETOCONAZOLE; LEUPRORELIN; METFORMIN; NAFARELIN; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SPIRONOLACTONE;

ADRENAL DISEASE; ADVERSE DRUG REACTION; CLINICAL EXAMINATION; COPING BEHAVIOR; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRY SKIN; ENDOCRINE DISEASE; FEMALE; FEMININITY; HAIR GROWTH; HIRSUTISM; HUMAN; HYPERTRICHOSIS; IDIOPATHIC DISEASE; LIFESTYLE MODIFICATION; LIVER DISEASE; LOW DRUG DOSE; MENSTRUATION DISORDER; NAUSEA AND VOMITING; OVARY DISEASE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PRURITUS; REVIEW; SELF ESTEEM; SIDE EFFECT; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT;

ANDROGEN ANTAGONISTS; DIAGNOSIS, DIFFERENTIAL; ENZYME INHIBITORS; FEMALE; GONADOTROPINS; HAIR REMOVAL; HIRSUTISM; HUMANS; HYPERTRICHOSIS; INSULIN RESISTANCE; LIFE STYLE;

EID: 84869161718     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2012.08.009     Document Type: Review

References (55)

1. Hatch R., Rosenfeld R.L., Kim M.H., et al. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981, 140:815-830.
2. Heithardt A.B., Barnes R.B. The diagnosis and management of hirsutism. Semin Reprod Med 2003, 21:285-293.
3. Blume-Peytavi U. An overview of unwanted female hair. Br J Dermatol 2011, 165:19-23.
4. Hillmann K., Blume-Peytavi U. Diagnosis of hair disorders. Semin Cutan Med Surg 2009, 28:33-38.
5. Blume-Peytavi U., Atkin S., Shapiro J., et al. European consensus on the evaluation of women presenting with excessive hair growth. Eur J Dermatol 2009, 19:597-602.
6. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol 2003, 101:995-1007.
7. Sanchez L.A., Knochenhauer E.S., Gatlin R., et al. Differential diagnosis of clinically evident hyperandrogenism: experience with over 1000 consecutive patients. Fertil Steril 2001, 76:S111.
8. O'Driscoll J.B., Mamtora H., Higginson J., et al. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia. Clin Endocrinol 1994, 41:231-236.
9. Morán C., Tapia M.C., Hernández E., et al. Etiologic review of hirsutism in 250 patients. Arch Med Res 1994, 25:311-314.
10. Waggoner W., Boots L.R., Azziz R. Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: a populational study. Gynecol Endocrinol 1999, 13:1-7.
11. Sonino N., Fava G.A., Mani E., et al. Quality of life of hirsute women. Postgrad Med J 1993, 69:186-189.
12. Barth J.H., Catalan J., Cherry C.A., et al. Psychological morbidity in women referred for treatment of hirsutism. J Psychosom Res 1993, 37:615-619.
13. Hahn S., Janssen O.E., Tan S., et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol 2005, 153:853-860.
14. Fruzzetti F., Perini D., Lazzarini V., et al. Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. Fertil Steril 2009, 92(2):626-634.
15. Codner E., Cassoria F. Puberty and ovarian function in girls with type 1 diabetes mellitus. Horm Res 2009, 71:12-21.
16. Souter I., Sanchez L.A., Perez M., et al. The prevalence of androgen excess among patients with minimal unwanted hair growth. Am J Obstet Gynecol 2004, 191:1914-1920.
17. Azziz R., Carmina E., Sawaya M.E. Idiopathic hirsutism. Endocr Rev 2000, 21:347-362.
18. Reingold S.B., Rosenfield R.L. The relationship of mild hirsutism or acne in women to androgens. Arch Dermatol 1987, 123:209-212.
19. Azziz R., Waggoner W.T., Ochoa T., et al. Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama. Fertil Steril 1998, 70:274-278.
20. Carmina E. Prevalence of idiopathic hirsutism. Eur J Endocrinol 1998, 139:421-423.
21. Barbieri R.L., Ryan K.J. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol 2012, 147:90-101.
22. Martin K.A., Chang R.J., Ehrmann D.A., et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008, 93:1105-1120.
23. Wajchenberg B.L., Albergaria Pereira M.A., Medonca B.B., et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000, 88:711-736.
24. Blume-Peytavi U., Hahn S. Medical treatment of hirsutism. Dermatol Ther 2008, 21:329-339.
25. Van der Spuy Z.M., le Roux P.A. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev 2003, CD003053.
26. Venturoli S., Marescalchi O., Colombo F.M., et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole and cyproterone acetate-oestrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999, 84:1304-1310.
27. Raudrant D., Rabe T. Progestogens with antiandrogenic properties. Drugs 2003, 63:463-492.
28. Crosby P.D., Rittmaster R.S. Predictors of clinical response in hirsute women treated with spironolactone. Fertil Steril 1991, 55:1076-1081.
29. Swiglo B.A., Cosma M., Flynn D.N., et al. Antiandrogens for the treatment of hirsutism: a systematic review and meta-analyses of randomized controlled trials. J Clin Endocrinol Metab 2008, 93:1153-1160.
30. Farquhar C., Lee O., Toomath R., et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev 2003, CD000194.
31. Ganie M.A., Khurana M.L., Eunice M., et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-label study. J Clin Endocrinol Metab 2004, 89:2756-2762.
32. Gregoriou O., Papadias K., Konidaris S., et al. Treatment of hirsutism with combied pill containing drospirenone. Gynecol Endocrinol 2008, 24:220-223.
33. Muderris I.I., Bayram F., Ozcelik B., et al. New alternative treatment in hirsutism: bicalutamide 25 mg/day. Gynecol Endocrinol 2002, 16:63-66.
34. Falsetti L., Gambera A., Legrenzi L., et al. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol 1999, 141:361-367.
35. Inal M.M., Yildirim Y., Taner C.E. Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. Fertil Steril 2005, 84:1693-1697.
36. Lakryc E.M., Motta E.L., Soares J.M., et al. The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism. Gynecol Endocrinol 2003, 17:57-63.
37. Malhotra B., Noveck R., Behr D., et al. Percutaneous absorption and pharmacokinetics of eflornithine HCL 13.9% cream in women with unwanted facial hair. J Clin Pharmacol 2001, 41:972-978.
38. Hickman J.G., Huber F., Palmisano M. Human dermal safety studies with eflornithine HCl 13.9% cream (Vaniqa), a novel treatment for excessive facial hair. Curr Med Res Opin 2001, 16:235-244.
39. Balfour J.A., McClellan K. Topical eflornithine. Am J Clin Dermatol 2001, 2:197-201.
40. Wolf J.E., Shander D., Huber F., et al. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Int J Dermatol 2007, 46:94-98.
41. Smith S.R., Piacquadio D.J., Beger B., et al. Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial. Dermatol Surg 2006, 32:1237-1243.
42. Hamzavi I., Tan E., Shapiro J., et al. A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. J Am Acad Dermatol 2007, 57:54-59.
43. Lord J.M., Flight I.H., Norman R.J. Insulin-sensitizing drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiroinositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003, CD003053.
44. Cosma M., Swiglo B.A., Flynn D.N., et al. Insulin sensitizers for the treatment of hirsutism: as systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2008, 93:1135-1142.
45. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356(24):2457-2471.
46. Dereli D., Dereli T., Bayraktar F., et al. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J 2005, 52:299-308.
47. Yilmaz M., Karakoc A., Toruner F.B., et al. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol 2005, 21:154-160.
48. Olsen E.A. Methods of hair removal. J Am Acad Dermatol 1999, 40:143-155.
49. Kopera D. Hair reduction: 48 months of experience with 800 nm diode laser. J Cosmet Laser Ther 2003, 5:146-149.
50. Ash K., Lord J., Newman J., et al. Hair remocal using a long-pulsed alexandrite laser. Dermatol Clin 1999, 17:387-399.
51. Nanni C.A., Alster T.S. Optimizing treatment parameters for hair removal using a topical carbon-based solution and 1064-nm Q-switched neodymium: YAG laser energy. Arch Dermatol 1997, 133:1546-1549.
52. Sanchez L.A., Perez M., Azziz R. Laser hair reduction in the hirsute patient: a critical assessment. Hum Reprod Update 2002, 8:169-181.
53. Guzzick D.S. Polycystic ovary syndrome. Obstet Gynecol 2004, 103:181-193.
54. Tang T., Lord J.M., Norman R.J., et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012, 5. CD003053.
55. Franks S. The investigation and management. J Fam Plann Reprod Health Care 2012, 38(3):182-186.